ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "etanercept"

  • Abstract Number: 2184 • 2013 ACR/ARHP Annual Meeting

    Application Of The Bonexpert Method For Bone Age and Bone Health Assessment In Patients With Juvenile Idiopathic Arthritis

    Charlotte M. Nusman1, Janneke Anink2, Lisette W.A. van Suijlekom-Smit2, Marion A.J. van Rossum3, Mario Maas4 and Rick R. van Rijn4, 1Department of Radiology, Academic Medical Center, Amsterdam, Netherlands, 2Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, 3Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, 4Radiology, Academic Medical Center, Amsterdam, Netherlands

    Background/Purpose: Both the maturation of bone and its mineral density are affected by chronic inflammation in juvenile idiopathic arthritis (JIA). Bone age is in most…
  • Abstract Number: 471 • 2013 ACR/ARHP Annual Meeting

    Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission

    Joaquín Borrás-Blasco1, Antonio Gracia-Pérez2, Dolores-Elvira Casterá1, J. Dolores Rosique-Robles1, Javier Abad1 and Alejandro González Álvarez3, 1Pharmacy Service, Hospital de Sagunto, Sagunto, Spain, 2Rheumatology Service, Hospital de Sagunto, Sagunto, Spain, 3Hospital Obispo Polanco, Teruel, Spain

    Etanercept 25 mg once weekly program for rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients in sustained clinical and radiological remissionBackground/Purpose: Etanercept 50mg/week (ETN50) has…
  • Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting

    Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis

    Sarah Thomas1, Nabeel Borazan2, Lewei Duan3, Nashla Barroso4, Sara Taroumian5, Banjamin Kretzmann6, Ricardo Bardales6 and Daniel Furst1, 1Medicine, University of California, Los Angeles, Los Angeles, CA, 2Medicine, Rheumatology UCLA, Los Angeles, CA, 3David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, 4Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, 5Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 6Rheumatology, University of California Los Angeles, los angeles, CA

    AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
  • Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting

    US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs

    Grant W. Cannon1, Scott L. DuVall2, Candace L. Hayden3, Liron Caplan4, Jeffrey R. Curtis5, Kaleb Michaud6, Ted R. Mikuls7, Andreas M. Reimold8, David H. Collier9, George Joseph9, David J. Harrison9 and Brian C. Sauer10, 1Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 2VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 3Epidemiology, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 4Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, 5Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, 9Amgen Inc., Thousand Oaks, CA, 10Epdemiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT

    Background/Purpose:  While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…
  • Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting

    Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics

    Antonio da Silva1, Ulrich Kronthaler1, Cornelius Fritsch2, Johann Poetzl3, Adelheid Rohde4, Anastassia Papandrikopoulou5, Hans-Peter Hofmann6 and Jan Marinus Visser1, 1Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, 2Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland, 3Bioanalytics, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, 4Characterisation, Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, 5Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, 6Pre-clinical, Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany

    Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
  • Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting

    Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis

    Bernard Combe1, Urs Kerkmann2, Fiona Brock3 and Gaia Gallo2, 1Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, 2Pfizer Europe, Rome, Italy, 3Quanticate, Hitchin, Hertfordshire, United Kingdom

    Background/Purpose:  Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…
  • Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting

    Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment

    Edward Bernton1 and Valerie Lowe2, 1Protalex Inc., Summit, NJ, 2Washington Biotechnology, Inc., Baltimore, MD

    Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that  is currently in Phase I trials in patients with active rheumatoid arthritis (RA).  SpA…
  • Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis

    Tamas Constantin1, Ivan Foeldvari2, Jelena Vojinovic3, Gerd Horneff4, Ruben Burgos-Vargas5, Irina Nikishina6, Jonathan Akikusa7, Tadej Avcin8, Jeffrey Chaitow5, Elena Koskova9, Bernard Lauwerys10, Jack Bukowski11, Chuanbo Zang12, Joseph Wajdula12, Deborah Woodworth12, Bonnie Vlahos13, Alberto Martini14 and Nicolino Ruperto5, 1Semmelweis University, Budapest, Hungary, 2Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 3Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, 4Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 5PRINTO, Genoa, Italy, 6Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, 7Rheumatology, Royal Childrens Hospital, Parkville, Australia, 8The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, 9National Institute of Rheumatic Diseases, Piestany, Slovakia, 10Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 11Department of Specialty Care, Pfizer Inc, Collegeville, PA, 12Pfizer Inc., Collegeville, PA, 13Department of Specialty Care, Pfizer Inc., Collegeville, PA, 14Pediatria II, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…
  • Abstract Number: 1826 • 2013 ACR/ARHP Annual Meeting

    Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding

    Bohdan P. Harvey and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
  • Abstract Number: 268 • 2013 ACR/ARHP Annual Meeting

    Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics

    Deborah Barthel1 and Gerd Horneff2, 1Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany

    Background/Purpose: Inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) treated with biologics. Methods: Baseline demografics, clinical characteristics…
  • Abstract Number: 1546 • 2013 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

    Maxime Dougados1, Wen-Chan Tsai2, Diego Luis Saaibi3, Randi Bonin4, Jack Bukowski5, Ronald Pedersen6, Bonnie Vlahos7 and Sameer Kotak8, 1Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 2Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan, 3MEDICITY S.A.S, Bucaramanga, Santander 681001, Colombia, 4Pfizer Inc, Collegeville, PA, 5Department of Specialty Care, Pfizer Inc, Collegeville, PA, 6Specialty Care, Pfizer Inc, Collegeville, PA, 7Department of Specialty Care, Pfizer Inc., Collegeville, PA, 8Specialty Care, Pfizer Inc., New York, NY

    Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). This analysis compares the impact of etanercept (ETN) vs…
  • Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting

    Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial

    In-Ho Song1, Kay-Geert A. Hermann2, Hildrun Haibel3, Christian Althoff4, Denis Poddubnyy3, Joachim Listing5, Anja Weiss6, Ekkehard Lange7, Bruce Freundlich8, Martin Rudwaleit9 and Joachim Sieper10, 1Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6German Rheumatism Research Centre, Berlin, Germany, 7BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, 8University of Pennsylvania, Philadelphia, PA, 9Endokrinologikum, Berlin, Germany, 10Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany

    Background/Purpose:   In patients with early axial spondyloarthritis (SpA) with a disease duration of
  • Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting

    Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial

    In-Ho Song1, Kay-Geert A. Hermann2, Hildrun Haibel1, Christian Althoff3, Denis Poddubnyy4, Joachim Listing5, Anja Weiss6, Ekkehard Lange7, Bruce Freundlich8, Martin Rudwaleit9 and Joachim Sieper4, 1Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Berlin, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6German Rheumatism Research Centre, Berlin, Germany, 7BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, 8University of Pennsylvania, Philadelphia, PA, 9Endokrinologikum, Berlin, Germany

    Background/Purpose:     < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
  • Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting

    Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept

    Michele Hooper1, Deborah Wenkert2, Bojena Bitman3, Virgil C. Dias4, Yessinia Bartley5, Julie Wang6 and Julia R. Gage7, 1Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, 2Inflammation TA, Amgen Inc., Thousand Oaks, CA, 3Amgen, Inc., San Francisco, CA, 4Amgen Inc., Thousand Oaks, CA, 5Assent Consulting, Solana Beach, CA, 6Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, 7Gage Medical Writing, LLC, Oak Park, CA

    Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263).  In 2011, the…
  • Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting

    Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure

    Bohdan P. Harvey1 and Zehra Kaymakcalan2, 1Biologics, Abbott Laboratories, Worcester, MA, 2Biologics, Abbott, Worcester, MA

    Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology